Analysts expect Alaunos Therapeutics, Inc. to report revenue of 0.00 for Q1 24, against a range of 0.00 to 0.00.
| Metric | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | - | - | - | - | ||||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 154.80 M | 151.70 M | 146.06 M | 160.94 M | ||||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 140.17 M | 139.70 M | 119.72 M | 134.32 M | ||||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 147.49 M | 145.70 M | 132.89 M | 147.63 M |
Analysts expect Alaunos Therapeutics, Inc. to report earnings per share of -4.67 for Q1 24, against a range of -4.95 to -4.39.
| Metric | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | - | - | - | - | ||||||||||||
| High Estimate | -4.39 | -3.97 | -4.05 | -4.31 | -6.38 | -4.62 | -4.98 | -3.33 | ||||||||||||
| Low Estimate | -4.95 | -4.65 | -4.39 | -4.89 | -7.16 | -5.46 | -5.40 | -3.83 | ||||||||||||
| Consensus Estimate | -4.67 | -4.31 | -4.22 | -4.60 | -6.77 | -5.04 | -5.19 | -3.58 |